Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M

KIORA PHARMACEUTICALS INC

2025-Q2 EPS reported -$1.10

Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.
KLARITY Phase 2 trial for KIO-104 in retinal inflammation initiated; patent exclusivity extended to 2043.
ABACUS-2 Phase 2 trial of KIO-301 for retinitis pigmentosa initiated with validated functional vision endpoint.
Option agreement with Senju for KIO-301 in Asia; potential deal value up to $110M plus royalties; $1.25M option fee received.
R&D expense $2.6M offset by $1.7M Théa reimbursement; G&A down to $1.4M from $1.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.